NextCure, Inc.
NXTC
NASDAQ·Healthcare·Biotechnology·Mkt cap $28.2M
$7.82
▼ -0.26%
P/E
—
Mkt Cap
$28.2M
52-Wk Range
$1.55–$15.74
52-Week Range
$1.55 - $15.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 58.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel immune checkpoint targets with limited competition
- Yale University licensing agreement providing cutting-edge research access
- Diversified pipeline across multiple immunomodulatory pathways
- Early-stage positioning with significant upside potential and reduced market competition
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Phase II advancement of NC318 and potential for expanded clinical trials
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+165.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NXTC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of -$2.80 vs -$1.95 consensus (-43.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-43.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 15, 2026
vs Industry
How NXTC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.